The Ongoing Ozempic Debate: Unpacking the Role of GLP-1 Agonists in Weight Loss and Health
Ozempic, Wegovy, and Mounjaro: Weighing the Benefits and Risks of GLP-1 Agonists The conversation around GLP-1 agonists like Ozempic, Wegovy, Mounjaro, Semaglutide , and Tirzepatide is becoming more prominent. With a wide range of opinions on their use and concerns over side effects, the discussion is often confusing. Recently, I listened to a podcast featuring Dr. Kimberly Anne Gudzune, MD, MPH on episode #405 of The Curbsiders Internal Medicine Podcas t , . The topic centered on GLP-1 agonists as tools for weight loss and managing obesity. The podcast offers key insights into the U.S. obesity epidemic, where 42% of adults are classified as obese by the Centers for Disease Control and Prevention (CDC) . The episode underlined the importance of personalized treatments rather than one-size-fits-all approaches for weight management. GLP-1 agonists, like Ozempic and Wegovy , work by mimicking natural peptides that regulate appetite and insulin response, leading to weight loss and ...